Factors affecting the level of adiponectin in the early post-infarction period

Myocardial infarction is a condition in which a number of hemodynamic, inflammatory and metabolic disorders occur. After myocardial infarction, many patients have a poor prognosis. In this regard, there is an urgent need for a quantitative blood test biomarker that would effectively assess the state and reserve of the heart muscle, as well as the prognosis in the early post-infarction period. Recent studies have paid great attention to the role of adiponectin in the prognosis of adverse cardiovascular events in the post-infarction period. Many studies have focused on the role of adiponectin in cardiovascular disease, but its role in the post-infarction period is controversial. The aim of the study was to study the gender characteristics of the adiponectin level in the early post-infarction period (30-40 days), in patients who underwent coronary stenting, as well as to determine the relationship of this biomarker with epicardial fat thickness and coronary artery stenosis of the 4^th degree. The study included 93 patients (55 men and 38 women) with a first-time myocardial infarction who underwent coronary revascularization. The patients were randomized into groups. Patients of the first group (37 men and 18 women) did not receive therapy for the prevention of cardiovascular diseases before the first myocardial infarction. Patients of the second group (18 men and 20 women) received therapy for the prevention of cardiovascular diseases. Therapy aimed at the prevention of cardiovascular diseases (arterial hypertension, stable angina pectoris) included regular intake of beta-blockers, angiotensin-converting enzyme inhibitors, statins and antiplatelet agents. The study revealed: stenosis of the 4^th degree of the 1st coronary vessel is significantly more common in men who do not receive therapy for the prevention of cardiovascular diseases before the first myocardial infarction; stenosis of the 4^th degree of the 2^nd coronary vessels was significantly more common in men receiving therapy for the prevention of cardiovascular diseases before the first myocardial infarction; high levels of adiponectin in the early post-infarction period are associated with multivessel damage to the coronary arteries, regardless of the received therapy for the prevention of cardiovascular diseases before the first myocardial infarction.

1. Hausenloy D. J., Chilian W., Crea F., Davidson S. M., Ferdinandy P., Garcia-Dorado D., van Royen N., Schulz R., Heusch G. The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection // Cardiovasc Res. 2019; 115 (7): 1143-1155.

2. Lau W. B., Ohashi K., Wang Y., Ogawa H., Murohara T., Ma X. L., Ouchi N. Role of Adipokines in cardiovascular disease // Circulat J. 2017; 81 (7): 920-928.

3. Marsche G., Zelzer S., Meinitzer A., Kern S., Meissl S., Pregartner G., Weghuber D., Almer G., Mangge H. Adiponectin Predicts High-Density Lipoprotein Cholesterol Efflux Capacity in Adults Irrespective of Body Mass Index and Fat Distribution. J Clin Endocrinol Metab. 2017; 102 (11): 4117-4123.

4. Choi H. M., Doss H. M., Kim K. S. Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases // Int J Mol Sci. 2020; 21 (4): 1219.

5. Li Q., Lu Y., Sun L., Yan J., Yan X., Fang L., Li M., Fan Z. Plasma adiponectin levels in relation to prognosis in patients with angiographic coronary artery disease // Metab Clin Exp. 2012; 61 (12): 1803-1808.

6. Zhao S., Kusminski C. M., Scherer P. E. Adiponectin, Leptin and Cardiovascular Disorders // Circ Res. 2021; 128 (1): 136-149.

7. Kishida K., Funahashi T., Shimomura I. Adiponectin as a routine clinical biomarker // Best Pract Res Clin Endocrinol Metab. 2014; 28 (1): 119-130.

8. Lisowska A., Lisowski P., Knapp M., Tycinska A., Sawicki R., Malyszko J., Hirnle T., Musial WJ. Serum adiponectin and markers of endothelial dysfunction in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG) // Adv Med Sci. 2014; 59 (2): 245-253.

9. Lindsay R. S., Resnick H. E., Zhu J., et al. Adiponectin and coronary heart disease: the Strong Heart Study // Arterioscler Thromb Vasc Biol. 2005; 25: 15-16.

10. Lawlor D. A., Davey Smith G., Ebrahim S., et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women // J Clin Endocrinol Metab. 2005; 90: 5677-5683.

11. Nomura H., Arashi H., Yamaguchi J., Ogawa H., Hagiwara N. Relation of Adiponectin to Cardiovascular Events and Mortality in Patients With Acute Coronary Syndrome // Am J Cardiol. 2021; 140: 7-12.

12. Lindberg S., Pedersen S. H., Mogelvang R., et al. Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention // Am J Cardiol. 2012; 109: 492-496.

13. Kistorp C., Faber J., Galatius S., Gustafsson F., Frystyk J., Flyvbjerg A., Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure // Circulation. 2005; 112: 1756-1762.

14. Cavusoglu E., Ruwende C., Chopra V., Yanamadala S., Eng C., Clark LT., et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain // Eur Heart J. 2006; 27: 2300-2309.

15. Kadoglou N. P. E., Velidakis N., Khattab E., Kassimis G., Patsourakos N. The interplay between statins and adipokines. Is this another explanation of statins' 'pleiotropic' effects? // Cytokine. 2021; 148: 155698.